Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)

被引:11
作者
Salhotra, Amandeep [1 ]
Aribi, Ahmed [1 ]
Ngo, Dat [2 ]
Zhang, Jianying [3 ]
Sandhu, Karamjeet [1 ]
Al-Malki, Monzr [1 ]
Ali, Haris [1 ]
Koller, Paul [1 ]
Arslan, Shukaib [1 ]
Budde, Elizabeth [1 ]
Khaled, Samer [1 ]
Dadwal, Sanjeet [4 ]
Snyder, David S. [1 ]
Artz, Andrew [1 ]
Forman, Stephen [1 ]
Nakamura, Ryotaro [1 ]
Stein, Anthony [1 ]
Marcucci, Guido [1 ]
Aldoss, Ibrahim [1 ]
Pullarkat, Vinod [1 ]
机构
[1] City Hope Natl Med Ctr, Dept Hematol & HCT, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Clin Pharmacol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Dept Informat Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA
[4] City Hope Natl Med Ctr, Div Infect Dis, 1500 E Duarte Rd, Duarte, CA 91010 USA
关键词
THERAPY;
D O I
10.1002/ajh.26157
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:E196 / E200
页数:5
相关论文
共 6 条
[1]   Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure [J].
Ball, Brian J. ;
Famulare, Christopher A. ;
Stein, Eytan M. ;
Tallman, Martin S. ;
Derkach, Andriy ;
Roshal, Mikhail ;
Gill, Saar, I ;
Manning, Benjamin M. ;
Koprivnikar, Jamie ;
McCloskey, James ;
Testi, Rebecca ;
Prebet, Thomas ;
Al Ali, Najla H. ;
Padron, Eric ;
Sallman, David A. ;
Komrokji, Rami S. ;
Goldberg, Aaron D. .
BLOOD ADVANCES, 2020, 4 (13) :2866-2870
[2]   Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia [J].
DiNardo, C. D. ;
Jonas, B. A. ;
Pullarkat, V. ;
Thirman, M. J. ;
Garcia, J. S. ;
Wei, A. H. ;
Konopleva, M. ;
Doehner, H. ;
Letai, A. ;
Fenaux, P. ;
Koller, E. ;
Havelange, V. ;
Leber, B. ;
Esteve, J. ;
Wang, J. ;
Pejsa, V. ;
Hajek, R. ;
Porkka, K. ;
Illes, A. ;
Lavie, D. ;
Lemoli, R. M. ;
Yamamoto, K. ;
Yoon, S. -S. ;
Jang, J. -H. ;
Yeh, S. -P. ;
Turgut, M. ;
Hong, W. -J. ;
Zhou, Y. ;
Potluri, J. ;
Pratz, K. W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :617-629
[3]   CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia [J].
Lancet, Jeffrey E. ;
Uy, Geoffrey L. ;
Cortes, Jorge E. ;
Newell, Laura F. ;
Lin, Tara L. ;
Ritchie, Ellen K. ;
Stuart, Robert K. ;
Strickland, Stephen A. ;
Hogge, Donna ;
Solomon, Scott R. ;
Stone, Richard M. ;
Bixby, Dale L. ;
Kolitz, Jonathan E. ;
Schiller, Gary J. ;
Wieduwilt, Matthew J. ;
Ryan, Daniel H. ;
Hoering, Antje ;
Banerjee, Kamalika ;
Chiarella, Michael ;
Louie, Arthur C. ;
Medeiros, Bruno C. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) :2684-+
[4]   Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting [J].
Nilsson, Christer ;
Hulegardh, Erik ;
Garelius, Hege ;
Mollgard, Lars ;
Brune, Mats ;
Wahlin, Anders ;
Lenhoff, Stig ;
Frodin, Ulla ;
Remberger, Mats ;
Hoglund, Martin ;
Juliusson, Gunnar ;
Stockelberg, Dick ;
Lehmann, Soren .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (09) :1770-1778
[5]   Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study [J].
Ostgard, Lene Sofie Granfeldt ;
Medeiros, Bruno C. ;
Sengelov, Henrik ;
Norgaard, Mette ;
Andersen, Mette Klarskov ;
Dufva, Inge Hogh ;
Friis, Lone Smidstrup ;
Kjeldsen, Eigil ;
Marcher, Claus Werenberg ;
Preiss, Birgitte ;
Severinsen, Marianne ;
Norgaard, Jan Maxwell .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) :3641-+
[6]   Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia [J].
Sandhu, Karamjeet S. ;
Dadwal, Sanjeet ;
Yang, Dongyun ;
Mei, Matthew ;
Palmer, Joycelynne ;
Salhotra, Amandeep ;
Al Malki, Monzr ;
Aribi, Ahmed ;
Ali, Haris ;
Khaled, Samer ;
Forman, Stephen J. ;
Snyder, David ;
Nakamura, Ryotaro ;
Stein, Anthony S. ;
Marcucci, Guido ;
Aldoss, Ibrahim ;
Pullarkat, Vinod .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (12) :E322-E327